Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 317

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 317
---
MC has the capability of adding new supplier relationships to expand RMC’s product portfolio for the hospitals and clinics who are actual customers and with whom RMC retains relationships. In connection with Choloc’s services as a financial advisor to the BLAC M&A Committee, BLAC agreed to pay Choloc an aggregate fee of $45,000. In addition, BLAC has agreed to reimburse certain of Choloc’s expenses arising, and to indemnify Choloc against certain liabilities that may arise, out of Choloc’s engagement. None of Choloc’s fee was contingent on the consummation of the Business Combination. In the two -yearperiod prior to the date of Choloc’s opinion, Choloc has not been engaged to provide financial advisory or other services to BLAC or OSR Holdings and Choloc has not received any compensation from BLAC or OSR Holdings during this period. Choloc was selected to act as the fairness opinion provider to the BLAC M&A Committee because of its qualifications and expertise in valuing early -stagelife sciences companies, as well as its familiarity with the business of OSR Holdings, including the fact that OSR Holdings and its operations are primarily located in Korea. Choloc’s opinion is not intended to and does not constitute a recommendation to any BLAC stockholder as to how such stockholder should vote or act with respect to the transaction or any matter relating thereto. BLAC M&A Committee’s engagement of AF for valuation services AF was engaged by the BLAC M&A Committee in April 2024 to prepare financial models on Darnatein and Vaximm based on various sets of assumptions, including business and cash flow projections, probability of preclinical and clinical development scenarios, markets and pricing, and competitive landscape. AF did not independently verify the information that it was provided in connection with the analyses and AF did not and does not render an opinion on the fairness of the transaction. AF understands its analyses have been provided to and relied upon by Choloc in connection with Choloc’s preparation of its fairness opinion. The Scope of AF’s services •Review the financial information and assumptions presented by BLAC; •Provide support for rNPV model developments based on information supplied by BLAC; and •Develop excel -basedvaluation models for Darnatein and Vaximm based on the foregoing. Fees In connection with AF’s engagement, BLAC agreed to pay AF an aggregate fee of KRW 30,000,000 (V